| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/18/2002 | WO2002055068A2 Cysteine for oral administration for dry eye treatment |
| 07/18/2002 | WO2002055067A2 Fumaric acid derivatives as nf-kappab inhibitors |
| 07/18/2002 | WO2002055066A1 Fumaric acid derivatives as nf-kappa-b inhibitors |
| 07/18/2002 | WO2002055065A2 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | WO2002055064A2 Mucopolysaccharidosis therapies |
| 07/18/2002 | WO2002055063A2 Fumaric acid amides |
| 07/18/2002 | WO2002055062A2 Pharmaceutical tablet comprising paroxetine mesylate |
| 07/18/2002 | WO2002055059A2 Method for preparing submicron particle suspensions |
| 07/18/2002 | WO2002055055A2 Fast-acting antimicrobial lotion with enhanced efficacy |
| 07/18/2002 | WO2002055049A1 Cosmetic and/or pharmaceutical preparations |
| 07/18/2002 | WO2002055048A1 Cosmetic and/or pharmaceutical preparations |
| 07/18/2002 | WO2002055027A2 Placebo effect and relaxation response |
| 07/18/2002 | WO2002055025A2 Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection |
| 07/18/2002 | WO2002055022A2 Active metabolite of antifungal compound |
| 07/18/2002 | WO2002055020A2 Topical testosterone formulations and associated methods |
| 07/18/2002 | WO2002055017A2 Method of treating autoimmune diseases |
| 07/18/2002 | WO2002055016A2 INHIBITION OF NF-λB BY TRITERPENE COMPOSITIONS |
| 07/18/2002 | WO2002055014A2 Therapeutic chroman compounds |
| 07/18/2002 | WO2002055013A2 Therapeutic chromone compounds |
| 07/18/2002 | WO2002055012A2 Therapeutic heterocyclic compounds |
| 07/18/2002 | WO2002055010A2 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/18/2002 | WO2002055009A1 Spaced drug delivery system |
| 07/18/2002 | WO2002054997A1 Devices for local and systemic delivery of active substances and methods of manufacturing thereof |
| 07/18/2002 | WO2002054933A2 Method for photodynamic therapy and applicator for carrying out said therapy |
| 07/18/2002 | WO2002054872A1 Liquid antimicrobial compositions |
| 07/18/2002 | WO2002054868A2 Pulmonary delivery of polyene antifungal agents |
| 07/18/2002 | WO2002041834A3 Atorvastatin hemi-calcium form vii |
| 07/18/2002 | WO2002041831A3 Inositol derivatives for increasing chloride secretion and inhibiting inflammation |
| 07/18/2002 | WO2002039978A8 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 07/18/2002 | WO2002038134A3 Multilayered supporting construction for plaster systems containing an active ingredient |
| 07/18/2002 | WO2002036552A8 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| 07/18/2002 | WO2002034699A3 Mammalian metabolites of a tachykinin receptor antagonist |
| 07/18/2002 | WO2002034280A3 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 07/18/2002 | WO2002034206A3 Felodipine transdermal device and methods |
| 07/18/2002 | WO2002032876A3 Novel m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence |
| 07/18/2002 | WO2002030377A3 Product for cleaning teeth and/or the mouth |
| 07/18/2002 | WO2002028418B1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 07/18/2002 | WO2002028414B1 Compositions and methods for wt1 specific immunotherapy |
| 07/18/2002 | WO2002028351A3 Recombinant mucin binding proteins from steptococcus pneumoniae |
| 07/18/2002 | WO2002024661A3 New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| 07/18/2002 | WO2002024184A3 Mechanically stable dosage forms containing ubiquinones |
| 07/18/2002 | WO2002022558A3 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 07/18/2002 | WO2002022557A3 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 07/18/2002 | WO2002022109A3 Patch comprising diclofenac |
| 07/18/2002 | WO2002020481A3 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine |
| 07/18/2002 | WO2002019978A3 Use of ectoine or ectoine derivatives for oral care |
| 07/18/2002 | WO2002019894A3 Methods for analyzing and using data from hypertensive patients |
| 07/18/2002 | WO2002016358A3 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| 07/18/2002 | WO2002016355A3 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |
| 07/18/2002 | WO2002016310A9 Selective androgen receptor modulators and methods of use thereof |
| 07/18/2002 | WO2002015937A3 Pharmaceutical composition for the systematic administration of pharmacologically active ingredients containing polyol fatty acid esters |
| 07/18/2002 | WO2002015868A3 Cosmetic formulation containing at least one di-sugar alcohol phosphate of c3 to c6 sugar alcohols |
| 07/18/2002 | WO2002013758A3 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 07/18/2002 | WO2002012249A3 Substituted pyrrole compounds and their use as spla2 inhibitors |
| 07/18/2002 | WO2002012224A3 Bicyclic compounds as h3 receptor ligands |
| 07/18/2002 | WO2002011704A3 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 07/18/2002 | WO2002009713A3 Selective pde 2 inhibitors, used as medicaments for improving cognition |
| 07/18/2002 | WO2002009680A3 Pharmacologically active substance for treating cardiovascular disorders |
| 07/18/2002 | WO2002008198A3 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 07/18/2002 | WO2002007766A3 Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia |
| 07/18/2002 | WO2002007737B1 Method for the treatment of glaucoma and ocular hypertension by administering nucleotides |
| 07/18/2002 | WO2002007722A3 Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 07/18/2002 | WO2002006242A3 5-substituted 2-aryl-4-pyrimidinones |
| 07/18/2002 | WO2002006218A3 STABILIZED 1α-HYDROXY VITAMIN D |
| 07/18/2002 | WO2002005827A3 Use of natural products in cancer treatment |
| 07/18/2002 | WO2002003989A3 Use of substituted indole compounds for treating sphincter incontinence |
| 07/18/2002 | WO2002003912A3 Novel c-4 substituted retinoids |
| 07/18/2002 | WO2002002143A3 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 07/18/2002 | WO2001096299A3 Indole derivatives and their use as 15-lipoxygenase inhibitors |
| 07/18/2002 | WO2001095936A3 Monoterpenes and sesquiterpenes as radiation sensitizers |
| 07/18/2002 | WO2001094345A3 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione |
| 07/18/2002 | WO2001090103A3 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 07/18/2002 | WO2001089517A3 Inhibition of cell proliferation and matrix synthesis by antioxidants and nad(p)h oxidase inhibitors |
| 07/18/2002 | WO2001089499A3 Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer |
| 07/18/2002 | WO2001089471A3 External skin preparations for suppressing sebum secretion |
| 07/18/2002 | WO2001085790A3 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 07/18/2002 | WO2001083503A3 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 07/18/2002 | WO2001083480A3 Dihydropyridine compounds and methods of use |
| 07/18/2002 | WO2001082933A3 Compositions and methods for stabilizing modified tissue |
| 07/18/2002 | WO2001082932A3 Methods and compositions for enhancing cellular function through protection of tissue components |
| 07/18/2002 | WO2001082920A3 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist |
| 07/18/2002 | WO2001081307A3 Triaryl cation antibiotics from environmental dna |
| 07/18/2002 | WO2001080847A3 Combination of carboxyalkylethers with antihypertensives and pharmaceutical use |
| 07/18/2002 | WO2001077072A3 Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality |
| 07/18/2002 | WO2001074340A3 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
| 07/18/2002 | WO2001072822A3 Genes involved in intestinal inflammatory diseases and use thereof |
| 07/18/2002 | WO2001072728A3 Novel piperazine derivatives |
| 07/18/2002 | WO2001072685A3 Polyamine analogues as cytotoxic agents |
| 07/18/2002 | WO2001068705A3 Il-17 receptor like molecules and uses thereof |
| 07/18/2002 | WO2001068142A9 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 07/18/2002 | WO2001068065A9 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 07/18/2002 | WO2001066747A3 Proteins named fctrx and nucleic acids encoding same |
| 07/18/2002 | WO2001064219A3 Use of cytoskeleton modifying compounds against intracranial pressure changes |
| 07/18/2002 | WO2001064201A3 Restricting reinstatement of drug use |
| 07/18/2002 | WO2001062263A3 Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome |
| 07/18/2002 | WO2001060400B1 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 07/18/2002 | WO2001060370A1 Remedies for endothelin-induced diseases |
| 07/18/2002 | WO2001056547A3 Preparation of aqueous clear solution dosage forms with bile acids |
| 07/18/2002 | WO2001049295A9 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/18/2002 | WO2001045679A3 Use of chemotherapeutic agents for topical treatment |